SOURCE: Xtalks

Xtalks Webinars

October 15, 2014 07:05 ET

Seizing the Future in Oncology: Improving the Clinical Development of Immunotherapies, Live Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - October 15, 2014) - This webinar will discuss key considerations in the development of immuno-oncology therapeutics. Join this interactive webinar to learn more on Thursday, October 23, 2014 at 10am EDT (NA) / 4pm BST (UK GMT +1).

Recent development of drugs targeting immune checkpoint proteins have shown high efficacy and long term patient benefit. As a result, there is great excitement in the pharmaceutical and oncology fields as these drugs promise to truly restore immune anti-tumor activity to broad patient populations across many indications. Cancer vaccines have also shown promise based on advances of adjuvants, combinations, biomarkers and new targets. However, the complexity of the immune system and tumor biology as well as comorbities and concomitant therapies may slow progress in immune-oncology clinical development. One early example of the impact of this complexity is seen in the challenges of patient enrichment and companion diagnostic development for PD-1/PD-L1 targeted drugs especially in combination studies. Another important lesson learned is determining the most appropriate endpoint for an immunotherapy as early use of the RECIST confounded investigators. Nevertheless, the immune system offers many future targets for immune checkpoint inhibitors, targeted immunomodulators and drug combinations including cancer vaccines.

The landscape for immunotherapies in oncology is expected to expand greatly in the near future as the initial checkpoint inhibitors come to market while development continues on broad immunomodulators and cancer vaccines. Follow-up checkpoint inhibitors targeting LAG3, OX40 and other novel proteins and novel combinations may provide new options for cancer patients. The complexity of the immune system and tumor biology also offers a wealth of biomarkers and potential targeted indications and patient populations. New diagnostic tools such as more powerful and better standardized flow cytometry and nex-gen sequencing can better profile immune response and utilize the immune repertoire for patient selection. Application of these tools in clinical development and patient care has yet to be fully exploited. Optimal clinical strategies including drug dose and schedule to mimimize risk of toxicity and the most appropriate clinical endpoints must address the unique mechanisms of action of these drugs.

As the field moves beyond initial successes, it will be important to explore these biomarker opportunities as well as address the critical questions in clinical trial design to best advance immuno-oncology clinical research.

The panel from Quintiles including Chris Learn, Senior Clinical Project Manager, Brad Smith, Vice President of Translational Medicine, and Eric Groves, Vice President of Center for Integrated Drug Development, will discuss key considerations in the development of immuno-oncology therapeutics such as:

  • The commercial and drug development landscape including immunomodulators, immune checkpoint inhibitors and cancer vaccines.
  • Technologies and biomarkers for pharmacodynamic and patient enrichment strategies
  • Options for measuring patient response and study endpoints for immuno-therapies
  • Current and future therapeutic approaches and combinations for improving immune anti-tumor activity and patient outcomes

The audience can expect to gain the following insights:

  • A high level overview of the current state of immuno-therapies in oncology
  • Insights into future opportunities for new immuno-oncology targets, biomarkers, therapeutic approaches and precision medicine
  • An understanding of the scientific and clinical considerations in designing immuno-therapy studies and treatment options
  • An appreciation for the requirements for translating a biomarker and assay into a companion diagnostic.

To learn more about this event visit: Seizing the Future in Oncology: Improving the Clinical Development of Immunotherapies

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2014/10/14/11G023806/Images/quintiles_logo_x_200-887496335075.jpg

Contact Information